Evidence map›Paper›PMID 37249637›Full record

ArticleCellular and molecular life sciences : CMLS2023

Cell density-dependent membrane distribution of ganglioside GM3 in melanoma cells.

Motohide Murate, Noriko Yokoyama, Nario Tomishige, Ludovic Richert, Nicolas Humbert, Brigitte Pollet, Asami Makino, Nozomu Kono, Laura Mauri, Junken Aoki and 11 more

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Gangliosides and Membrane Microdomains.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  3. The Role of Cholesterol in M2 Clustering and Viral Budding Explained.Journal of chemical theory and computation · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 3 countries.

Motohide MurateLipid Biology Laboratory, RIKEN, Wako, Saitama, 351-0198, Japan. mmurate@riken.jp.
Noriko YokoyamaInstitute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Urayasu, Chiba, 279-0021, Japan.
Nario TomishigeLipid Biology Laboratory, RIKEN, Wako, Saitama, 351-0198, Japan.
Ludovic RichertLaboratoire de Bioimagerie et Pathologies, UMR 7021, CNRS, Faculté de Pharmacie, Université de Strasbourg, 67401, Illkirch, France.
Nicolas HumbertLaboratoire de Bioimagerie et Pathologies, UMR 7021, CNRS, Faculté de Pharmacie, Université de Strasbourg, 67401, Illkirch, France.
Brigitte PolletLaboratoire de Bioimagerie et Pathologies, UMR 7021, CNRS, Faculté de Pharmacie, Université de Strasbourg, 67401, Illkirch, France.
Asami MakinoLipid Biology Laboratory, RIKEN, Wako, Saitama, 351-0198, Japan.
Nozomu KonoDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
Laura MauriDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Junken AokiDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
Yasushi SakoCellular Informatics Laboratory, RIKEN CPR, Wako, Saitama, 351-0198, Japan.
Sandro SonninoDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Naoko KomuraInstitute for Glyco-Core Research, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan.
Hiromune AndoInstitute for Glyco-Core Research, Gifu University, 1-1 Yanagido, Gifu, 501-1193, Japan.
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8575, Japan.
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8575, Japan.
Kei-Ichiro InamoriDivision of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, 981-8558, Japan.
Jin-Ichi InokuchiDivision of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, 981-8558, Japan.
Yves MélyLaboratoire de Bioimagerie et Pathologies, UMR 7021, CNRS, Faculté de Pharmacie, Université de Strasbourg, 67401, Illkirch, France.
Kazuhisa IwabuchiInstitute for Environmental and Gender-Specific Medicine, Graduate School of Medicine, Juntendo University, Urayasu, Chiba, 279-0021, Japan. iwabuchi@juntendo.ac.jp.
Toshihide KobayashiLipid Biology Laboratory, RIKEN, Wako, Saitama, 351-0198, Japan. toshihide.kobayashi@unistra.fr.ORCID http://orcid.org/0000-0002-4811-7270
Centre National de la Recherche Scientifique · FRGifu University · JPJuntendo University · JPRIKEN · JPThe University of Tokyo · JPTohoku Medical and Pharmaceutical University · JPTohoku University · JPUniversity of Milan · ITObayashi (Japan) · JP

Funding

Agence Nationale de la Recherche ANR-19-CE16-0012-02Agence Nationale de la Recherche ANR-22-CE44-0019-01Japan Agency for Medical Research and Development JP22ama121008Japan Agency for Medical Research and Development JPam0401013Vaincre les Maladies Lysosomales 19/LBPH/S44
6 · The paper itself

Abstract

Monosialoganglioside GM3 is the simplest ganglioside involved in various cellular signaling. Cell surface distribution of GM3 is thought to be crucial for the function of GM3, but little is known about the cell surface GM3 distribution. It was shown that anti-GM3 monoclonal antibody binds to GM3 in sparse but not in confluent melanoma cells. Our model membrane study evidenced that monoclonal anti-GM3 antibodies showed stronger binding when GM3 was in less fluid membrane environment. Studies using fluorescent GM3 analogs suggested that GM3 was clustered in less fluid membrane. Moreover, fluorescent lifetime measurement showed that cell surface of high density melanoma cells is more fluid than that of low density cells. Lipidomics and fatty acid supplementation experiment suggested that monounsaturated fatty acid-containing phosphatidylcholine contributed to the cell density-dependent membrane fluidity. Our results indicate that anti-GM3 antibody senses GM3 clustering and the number and/or size of GM3 cluster differ between sparse and confluent melanoma cells.

Indexed as

G(M3) GangliosideMelanomaAntibodies, MonoclonalCell CountCell MembraneHumansAntibodies, MonoclonalG(M3) GangliosideAnti-ganglioside antibodiesCrypticityFluorescence lifetime imagingLipidomicsPlasma membrane

Identifiers

PMID37249637
PMCPMC11073213
OpenAlexW4378746188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.